A multicohort phase I trial evaluated the safety and efficacy of atezolizumab monotherapy in metastatic TNBC with at least 5% PD-L1 expression in tumor infiltrating immune cells (IC), later expanding to include patients with PD-L1- disease [12]. The gene discussed is CD274; the disease is neoplasm.